Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency

Journal of Clinical Immunology

Volumn 32, Issue 4, 2012, Pages 663-669

  Wasserman, Richard L ^a   Church, Joseph A ^b   Stein, Mark ^c   Moy, James ^d   White, Martha ^e   Strausbaugh, Steven ^f   Schroeder, Harry ^g   Ballow, Mark ^h   Harris, James ⁱ   Melamed, Isaac ^j   Elkayam, David ^k   Lumry, William ^l   Suez, Daniel ^m   Rehman, Syed M ⁿ  

^a Pediatric Allergy/Immunology Associates   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Allergy Associates of the Palm Beaches   (United States)

^d RUSH UNIVERSITY   (United States)

^e Institute for Asthma and Allergy   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h CHILDREN S HOSPITAL OF BUFFALO   (United States)

ⁱ South Bend Clinic LLP   (United States)

^j 1st Allergy and Clinical Research Center ^*  (United States)

^k Bellingham Asthma Allergy and Immunology Clinic   (United States)

^l Allergy and Asthma Specialists   (United States)

^m Allergy   (United States)

ⁿ Allergy and Asthma Center   (United States)

more..

Author keywords

Clinical trial; Efficacy; Intravenous immunoglobulin (IVIG); Pharmacokinetics; Primary immunodeficiency (PID); Safety

Indexed keywords

IMMUNOGLOBULIN;

ABSENTEEISM; ACUTE SINUSITIS; ADOLESCENT; ADULT; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD PRESSURE; BRONCHITIS; CHILD; CHRONIC SINUSITIS; CLINICAL CHEMISTRY; CONJUNCTIVITIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; FATIGUE; FEMALE; GASTROINTESTINAL INFECTION; HEMATOLOGICAL PARAMETERS; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RATE; INJECTION SITE REACTION; LETHARGY; LIQUID; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OTITIS MEDIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL SIGN;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; BACTERIAL INFECTIONS; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GENETIC DISEASES, X-LINKED; HUMANS; IGG DEFICIENCY; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84863988451     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9656-5     Document Type: Article

References (16)

1. Bruton OC. Agammaglobulinema. Pediatrics. 1952;9:722-7.
2. Cohn EJ, Strong LE, Hughes Jr WL, et al. Preparation and properties of serum and plasma proteins III: A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459-75.
3. Melin JL, Oncley M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and betalipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71:541-50.
4. Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986;6:210-3. (Pubitemid 16139680)
5. Mitra G, Wong MF, Mozen MM, McDougal JS, Levy JA. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion. 1986;26:394-7. (Pubitemid 16056288)
6. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 1992;32:824-8. (Pubitemid 23001626)
7. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives I: Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion. 1985;25:516-22. (Pubitemid 16174459)
8. Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion. 2002;42:1005-10.
9. FDA/CBER. Guidance for industry: Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (Human) as replacement therapy for primary humoral immunodeficiency, http://www.fda.gov. cber/gdlns/igivimmuno. htm, June 2008.
10. Ochs HD, Pinciaro PJ, et al. Octagam® 5%, an Intravenous IgG Product, is efficacious and well tolerated in patients with primary immunodeficiency diseases. J Clin Immunol. 2004;24(3):309-14. (Pubitemid 39030679)
11. Berger M, Pinciaro PJ, et al. Safety, efficacy and pharmacokinetics of flebogamma® 5% [Immune Globulin Intravenous (Human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol. 2004;24(4):389-96. (Pubitemid 39005571)
12. Berger M, et al. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628-33.
13. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-95. (Pubitemid 44051386)
14. Stein MR, Nelson RP, Church JA, Wasserman RL, Church JA, Wasserman RL, et al. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137-44.
15. Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, et al. Efficacy, pharmacokinetics, safety, and tolerability of flebogamma ® 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321-9.
16. Schiff RI. Intravenous gammaglobulin: Pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol. 1994;5:63-87. (Pubitemid 24215637)